Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Macrolide-Resistant Mycoplasma pneumoniae Infection: Epidemiology, Potential Pathogenic Mechanisms and Novel Therapeutic Strategies.

Created on 18 Nov 2026

Authors

Jialin Zhao, Zijie Li, Yuefei Jin, Guangcai Duan

Published in

Microbial pathogenesis. Pages 108924. Nov 17, 2026. Epub Nov 17, 2026.

Abstract

Mycoplasma pneumoniae (MP) stands as one of the primary pathogens responsible for community-acquired pneumonia in children worldwide. Its macrolide-resistant Mycoplasma pneumoniae (MRMP) strains have become a serious clinical challenge. Resistance rates are unevenly distributed globally, reaching 70-100% among children in China, which substantially increases treatment difficulty and disease burden. MRMP is associated with prolonged fever and cough, higher treatment failure rates, and an elevated risk of both pulmonary and extrapulmonary complications. Resistance primarily results from point mutations in domain V of the 23S rRNA gene. Multiple studies have documented associations between MRMP infection, increased bacterial burden, virulence-associated factors, and dysregulated hyperinflammatory host responses. However, whether macrolide resistance mutations directly enhance virulence remains unresolved, as the observed associations could alternatively be confounded by delayed effective therapy, bacterial genetic background, and host factors. Currently, clinical treatment faces a dilemma: the efficacy of first-line macrolide antibiotics is declining, while alternative drugs such as tetracyclines and fluoroquinolones are restricted in children. To address this challenge, current research directions mainly include: developing new inhibitors targeting adhesion proteins and virulence factors; researching new antibiotics targeting resistance mechanisms; exploring immunomodulatory adjuvant therapies; and applying rapid molecular diagnostics to precise medication. Future priorities include strengthened global surveillance, optimized antibiotic stewardship, accelerated development of pediatric-appropriate drugs, and broader implementation of rapid diagnostic tests. Future research should focus on integrating pathogen characteristics with host response profiles to guide individualized therapy and improve clinical outcomes.

PMID:
43044691
Bibliographic data and abstract were imported from PubMed on 18 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement